Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Reckitt Expands 'OTC' Business, China Presence With Mead Johnson

Executive Summary

Marketing Enfamil and other Mead Johnson formula and nutritional brands, says RB CEO Rakesh Kapoor, is "very much in the core of what consumer health stands for," and also immediately doubles the size of the firm's consumer business.

You may also be interested in...



Post Expects Stronger Nutrition Business Value To Emerge On Its Own, Plans IPO

Planned IPO of 25% of shares in nutrition business targets unlocking value currently held down by Post's other units. Its competitors in cereal space as well as firms across broader food industry also may determine their acquired nutritional businesses could be higher valued operating separately.

Reckitt Begins CEO Search As Kapoor Departs The Company He Reshaped

Reckitt Benckiser's long-serving CEO, Rakesh Kapoor, has unexpectedly announced his intention to retire by the end of the year, with the company immediately kicking off the search for his replacement. Kapoor will be remembered for transforming RB's consumer health business, but also for a number of setbacks under his watch which have impacted results.

Reckitt Benckiser Gives Consumer Health Portfolio Its Own Home – What's Next?

UK manufacturer in January begins operating with a separate health care division, representing 60% of sales with products including Mucinex and Mead Johnson infant and adult formulas, and a home care/hygiene division led by Lysol disinfectants. The plan piques analysts' expectations that operating the divisions separately will lead to divesting one.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS120037

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel